📊 MDGL Key Takeaways
Is Madrigal Pharmaceuticals, Inc.. (MDGL) a Good Investment?
Madrigal demonstrates exceptional 432% revenue growth suggesting successful product commercialization, but is burning $167M in operating cash flow against only $227M cash reserves, creating ~16-month runway at current burn rates. While net losses are improving 38% YoY, the company remains deeply unprofitable (-30.3% net margin) with unsustainable cash burn and $340M debt burden, creating material near-term financing risk that outweighs growth momentum.
Why Buy Madrigal Pharmaceuticals, Inc.. Stock? MDGL Key Strengths
- Exceptional 432% year-over-year revenue growth indicating successful product adoption
- Improving profitability trajectory with net loss decreasing 38.1% YoY
- Strong short-term liquidity position with 3.50x current ratio and 3.16x quick ratio
MDGL Stock Risks: Madrigal Pharmaceuticals, Inc.. Investment Risks
- Severe cash burn of -$167.4M operating CF with only ~16 months of cash runway at current burn rates
- Company remains deeply unprofitable with -30.3% net margin and negative FCF of -171.3M
- High debt burden of $340.3M alongside cash burn creates material refinancing risk if profitability not achieved soon
- Operating income -$92.7M indicates core business operations are not self-sustaining
Key Metrics to Watch
- Operating cash flow trend and path to positive operating CF
- Operating margin progression toward breakeven with revenue growth
- Cash runway depletion rate and capital raise timeline requirements
- Timeline to GAAP profitability based on current cost structure
Madrigal Pharmaceuticals, Inc.. (MDGL) Financial Metrics & Key Ratios
💡 AI Analyst Insight
Strong liquidity with a 3.50x current ratio provides a solid financial cushion.
MDGL Profit Margin, ROE & Profitability Analysis
MDGL vs Healthcare Sector: How Madrigal Pharmaceuticals, Inc.. Compares
How Madrigal Pharmaceuticals, Inc.. compares to Healthcare sector averages
Sector benchmarks are approximate industry averages. Actual sector performance may vary.
Is Madrigal Pharmaceuticals, Inc.. Stock Overvalued? MDGL Valuation Analysis 2026
Based on fundamental analysis, Madrigal Pharmaceuticals, Inc.. shows some fundamental concerns relative to the Healthcare sector in 2026.
Note: This is a fundamental analysis based on SEC filings. For P/E ratio, price targets, and market-based valuation, consult financial data providers. This is not investment advice.
Madrigal Pharmaceuticals, Inc.. Balance Sheet: MDGL Debt, Cash & Liquidity
MDGL Revenue & Earnings Growth: 5-Year Financial Trend
5-Year Trend Summary: Madrigal Pharmaceuticals, Inc..'s revenue has grown significantly by 432% over the 5-year period, indicating strong business expansion. The most recent EPS of $-19.99 indicates the company is currently unprofitable.
MDGL Revenue Growth, EPS Growth & YoY Performance
MDGL Quarterly Earnings & Performance
| Quarter | Revenue | Net Income | EPS |
|---|---|---|---|
| Q1 2026 | $137.3M | -$73.2M | $-1.50 |
| Q3 2025 | $62.2M | -$42.3M | $-4.92 |
| Q2 2025 | $14.6M | -$42.3M | $-1.90 |
| Q1 2025 | N/A | -$73.2M | $-3.32 |
| Q3 2024 | N/A | -$76.9M | $-4.92 |
| Q2 2024 | N/A | -$76.9M | $-4.69 |
Data sourced from SEC EDGAR 10-Q quarterly filings. Figures may represent quarterly or cumulative values.
Madrigal Pharmaceuticals, Inc.. Dividends, Buybacks & Capital Allocation
MDGL SEC Filings: Latest 10-K & 10-Q Analysis
Access official SEC EDGAR filings for Madrigal Pharmaceuticals, Inc.. (CIK: 0001157601)
📋 Recent SEC Filings
❓ Frequently Asked Questions about MDGL
What is the AI rating for MDGL?
Madrigal Pharmaceuticals, Inc.. (MDGL) has an AI rating of SELL with 72% confidence, based on fundamental analysis of SEC EDGAR filings.
What are MDGL's key strengths?
Claude: Exceptional 432% year-over-year revenue growth indicating successful product adoption. Improving profitability trajectory with net loss decreasing 38.1% YoY.
What are the risks of investing in MDGL?
Claude: Severe cash burn of -$167.4M operating CF with only ~16 months of cash runway at current burn rates. Company remains deeply unprofitable with -30.3% net margin and negative FCF of -171.3M.
What is MDGL's revenue and growth?
Madrigal Pharmaceuticals, Inc.. reported revenue of $311.3M.
Does MDGL pay dividends?
Madrigal Pharmaceuticals, Inc.. does not currently pay dividends.
Where can I find MDGL SEC filings?
Official SEC filings for Madrigal Pharmaceuticals, Inc.. (CIK: 0001157601) including 10-K, 10-Q, and 8-K reports are available on SEC EDGAR.
What is MDGL's EPS?
Madrigal Pharmaceuticals, Inc.. has a diluted EPS of $-3.25.
How is the AI analysis conducted?
Two independent AI systems — Claude (Anthropic) and ChatGPT (OpenAI) — analyze SEC EDGAR filings including 10-K annual reports and 10-Q quarterly reports. Each AI evaluates financial health, profitability ratios, balance sheet strength, and growth metrics. The combined rating reflects both perspectives for balanced insights.
Is MDGL a good stock to buy right now?
Based on our AI fundamental analysis in May 2026, Madrigal Pharmaceuticals, Inc.. has a SELL rating with 72% confidence. Review the strengths and risks sections above before making a decision. This is not investment advice.
Is MDGL stock overvalued or undervalued?
Valuation metrics for MDGL: ROE of -17.4% (sector avg: 15%), net margin of -30.3% (sector avg: 12%). Compare these metrics with sector averages to assess valuation.
Should I buy MDGL stock in 2026?
Our dual AI analysis gives Madrigal Pharmaceuticals, Inc.. a combined SELL rating for 2026. Revenue is data pending, with profitability at or below sector average. Always conduct your own research.
What is MDGL's free cash flow?
Madrigal Pharmaceuticals, Inc..'s operating cash flow is $-167.4M, with capital expenditures of $3.8M. FCF margin is -55.0%.
How does MDGL compare to other Healthcare stocks?
Vs Healthcare sector averages: Net margin -30.3% (avg: 12%), ROE -17.4% (avg: 15%), current ratio 3.50 (avg: 2).